- Home
- BRUNW vs CDNA Comparison
BRUNW vs CDNA Comparison
Compare BRUNW & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRUNW | CDNA |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | BRUNW | CDNA |
|---|---|---|
| Price | $17.00 | $28.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 101.0K | ★ 932.9K |
| Earning Date | N/A | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $582.20 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $17.00 | $10.96 |
| 52 Week High | $29.00 | $30.00 |
Technical Indicators
Market Signals| Indicator | BRUNW | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 61.70 |
| Support Level | N/A | $14.59 |
| Resistance Level | $25.52 | $30.00 |
| Average True Range (ATR) | 3.00 | 1.32 |
| MACD | -0.60 | -0.05 |
| Stochastic Oscillator | 0.00 | 73.00 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.